Interstitial Lung Disease Clinical Trials in New York, New York

7 studies are recruiting for interstitial lung disease in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

   The purpose of this study to find out whether giving BIO 300 in combination with thoracic radiation therapy is effective in preventing pneumonitis in people with non-small cell lung cancer (NSCLC) and interstitial lung disease (ILD).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07323732 on ClinicalTrials.gov

2. DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

   This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).

   Stage

   Not phased

   Ages

   18 and older

   Site

   New York University Langone Medical Center, New York, New York

   Locations

   71 in total

   Run by

   United Therapeutics

   See if you can join NCT06388421 on ClinicalTrials.gov

3. PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

   This is a prospective, observational cohort study. Participants with non-idiopatic pulmonary fibrosis, interstitial lung disease (ILD) will be followed for 24 months to systematically collect clinical, imaging, and biospecimen data. The primary objective is to optimize progressive pulmonary fibrosi…

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Weill Cornell Medicine, New York, New York

   Locations

   24 in total

   Run by

   University of Massachusetts, Worcester

   See if you can join NCT06855329 on ClinicalTrials.gov

4. Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

   The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USA005, New York, New York

   Locations

   145 in total

   Run by

   Insmed Incorporated

   See if you can join NCT07179380 on ClinicalTrials.gov

5. Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

   Study RIN-PF-305 is designed to evaluate the safety and efficacy of inhaled treprostinil in subjects with progressive pulmonary fibrosis (PPF) over a 52-week period.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Weill Cornell Medicine, New York-Presbyterian Hospital, New York, New York

   Locations

   165 in total

   Run by

   United Therapeutics

   See if you can join NCT05943535 on ClinicalTrials.gov

6. An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH

   Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.

   Stage

   Not phased

   Ages

   18 to 80

   Site

   NYU Langone Medical Center, New York, New York

   Locations

   23 in total

   Run by

   Liquidia Technologies, Inc.

   See if you can join NCT06129240 on ClinicalTrials.gov

7. Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

   This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improv…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   aTyr Investigative Site, New York, New York

   Locations

   15 in total

   Run by

   aTyr Pharma, Inc.

   See if you can join NCT05892614 on ClinicalTrials.gov